Is Ozempic a Peptide? How Semaglutide Put Peptides on the Map

Few medicines have ever become as famous as quickly as Ozempic. Within a few years it went from a diabetes treatment most people had never heard of to a household name, discussed on news programmes, in celebrity gossip and around dinner tables. Along the way, it did something else: it made millions of people aware, many for the first time, of the word “peptide”. So is Ozempic actually a peptide? Yes. Its active ingredient, semaglutide, is a modified peptide hormone, and its story is one of the best illustrations of what peptide science can achieve.

This guide explains exactly what semaglutide is, how it was discovered and designed, how it works, what the landmark trials found, how it differs from steroids and from the research peptides sold for laboratory use, and why it has transformed interest in peptide science. It is an educational explainer about a licensed medicine, not medical advice. Crown Peptides does not supply semaglutide; we supply research peptides for laboratory research use only.

The Short Answer

Yes, Ozempic is a peptide medicine. Its active ingredient, semaglutide, is a chain of 31 amino acids closely modelled on GLP-1, a natural hormone made in the gut. It has been chemically modified so that it lasts about a week in the body rather than a few minutes. It is not a steroid, not a stimulant and not a hormone replacement in the usual sense: it is a long-acting copy of one of the body’s own signals.

Ozempic, Wegovy, Rybelsus: One Molecule, Several Names

Part of the confusion around Ozempic comes from the fact that the same molecule is sold under several brand names, for different purposes.

Ozempic

Ozempic is semaglutide licensed for type 2 diabetes, given once a week. It was first approved in the United States in 2017.

Wegovy

Wegovy is semaglutide licensed for weight management in people with obesity or overweight with related conditions, also given weekly, at a higher strength than Ozempic.

Rybelsus

Rybelsus is semaglutide in tablet form, a notable achievement because peptides are usually destroyed in the gut. It uses an absorption enhancer called SNAC that helps the peptide cross the stomach lining.

The common thread

All three contain the same peptide. The differences lie in the strength, the licensed use and the form, not in the molecule itself.

What Is GLP-1?

The gut’s fullness signal

GLP-1, short for glucagon-like peptide-1, is a peptide hormone made by specialised cells in the lining of the gut, called L cells, in response to food. It has several jobs. It prompts the pancreas to release insulin when blood sugar is high, reduces the release of glucagon, a hormone that raises blood sugar, slows the emptying of the stomach and acts on the brain to increase feelings of fullness.

The incretin effect

GLP-1 is one of two main “incretin” hormones. Scientists had long noticed that sugar taken by mouth triggers much more insulin release than the same amount of sugar given into a vein. The difference, called the incretin effect, is caused by gut hormones such as GLP-1 and GIP, released when food arrives in the gut.

The problem with natural GLP-1

Natural GLP-1 is broken down within about two minutes by an enzyme called DPP-4 and quickly cleared by the kidneys. That made it fascinating to study but useless as a medicine. The challenge was to make a version that lasted.

The Discovery Story: From Lizard Venom to Weekly Injections

The GLP-1 discovery

GLP-1 was identified in the 1980s, when researchers including Joel Habener, Svetlana Mojsov and Daniel Drucker in Boston and Jens Juul Holst in Copenhagen studied the gene for glucagon and found that it also coded for other peptides, one of which strongly stimulated insulin release. The significance of that finding took years to realise fully.

The Gila monster

One of the most famous chapters in the story involves a lizard. In 1992, John Eng, an endocrinologist at the Bronx Veterans Affairs Medical Center, isolated a peptide called exendin-4 from the venom of the Gila monster, a lizard native to the American south-west (PMID: 1313797). Exendin-4 turned out to act on the GLP-1 receptor, but, crucially, it resisted DPP-4 and lasted far longer than human GLP-1. A synthetic version, exenatide, was approved in 2005 as the first GLP-1 medicine.

Liraglutide: the first daily analogue

Novo Nordisk took a different approach, modifying human GLP-1 rather than borrowing from a lizard. Its first success, liraglutide, attached a fatty acid to GLP-1 so that it binds to albumin, the most abundant protein in the blood, which protects it from breakdown and slows its removal. Liraglutide lasted long enough for once-daily use. A 2019 review in Frontiers in Endocrinology by Knudsen and Lau told the story of liraglutide and semaglutide’s discovery and development (PMID: 31031702, PMC6474072).

Semaglutide: the weekly breakthrough

Semaglutide refined the same approach further. In a 2015 paper in the Journal of Medicinal Chemistry, Lau and colleagues at Novo Nordisk described its design: a substitution to block DPP-4, and a longer, optimised fatty acid chain attached through a flexible linker, which bound albumin more strongly while keeping high activity at the GLP-1 receptor (PMID: 26308095). The result lasted about a week in the body, making once-weekly treatment possible.

How Semaglutide Is Built

Close to human GLP-1

Semaglutide shares about 94% of its amino acid sequence with human GLP-1. That close similarity is part of why it acts so specifically on the GLP-1 receptor.

Three key modifications

First, the amino acid alanine at position 8 is replaced with aminoisobutyric acid, an unusual amino acid that DPP-4 cannot cut next to. Second, the lysine at position 34 is replaced with arginine, leaving a single lysine at position 26 as the attachment point. Third, a fatty acid chain, an 18-carbon diacid, is attached to that lysine through a linker. The fatty acid grips albumin in the blood, which acts like a slow-release reservoir.

Why that matters

These changes illustrate a principle that runs through all of peptide science: a natural peptide sequence provides precision, and careful chemical modifications provide durability. The same principles are used in research peptides such as CJC-1295 with DAC, which binds albumin to extend its action to about a week, and in Ipamorelin, which uses unusual amino acids to resist breakdown.

What the Landmark Trials Found

STEP 1

The trial that changed everything was STEP 1, published in the New England Journal of Medicine in 2021 (PMID: 33567185). It enrolled 1,961 adults with overweight or obesity who did not have diabetes, all receiving lifestyle support, and randomly assigned them to weekly semaglutide or placebo for 68 weeks. The mean change in body weight was -14.9% with semaglutide and -2.4% with placebo. Half of the semaglutide group lost 15% or more of their body weight, compared with fewer than 5% of the placebo group.

Side effects

The trial also documented side effects clearly. Nausea and diarrhoea were the most common, typically transient and mild to moderate and tending to ease over time, but more participants stopped treatment because of gastrointestinal events with semaglutide than with placebo.

Why the results mattered

Before STEP 1, medicines for weight management typically produced modest results. A reduction of around 15%, sustained over more than a year, was on a different scale, and it transformed how researchers and clinicians thought about obesity treatment, and about peptides.

Why Semaglutide Affects Appetite So Strongly

Semaglutide’s effect on weight comes mainly from reduced food intake rather than increased energy use. Several mechanisms combine to produce that effect.

Fullness signals in the brain

GLP-1 receptors in the hypothalamus and brainstem, the brain’s appetite control centres, respond to semaglutide by increasing feelings of fullness and reducing hunger. Studies have also examined effects on the brain’s reward circuits, which may help explain reports of reduced cravings.

Slower stomach emptying

GLP-1 slows the rate at which food leaves the stomach, which prolongs the feeling of fullness after a meal. This effect is also a major contributor to the nausea commonly reported, particularly early in treatment.

Better blood sugar control

By boosting insulin release when blood sugar is high and reducing glucagon, semaglutide smooths out blood sugar swings, which is its original purpose in type 2 diabetes.

Beyond Weight and Blood Sugar

As the GLP-1 medicines have been studied more widely, researchers have looked at effects well beyond their original purpose. A large cardiovascular outcomes trial of semaglutide in people with heart disease and overweight but without diabetes, known as SELECT and published in 2023, reported a reduction in major cardiovascular events compared with placebo. Other studies have examined effects on kidney disease, fatty liver disease and sleep apnoea, and research into possible effects on the brain and addictive behaviours is ongoing. These wider effects are part of why GLP-1 research has become one of the most active fields in medicine.

What Happens When Treatment Stops

An important finding from the semaglutide research is that its effects depend on continued treatment. In follow-up of STEP 1 participants after semaglutide was stopped, much of the weight lost was regained over the following year, and improvements in several cardiometabolic measures also reversed. This fits with how semaglutide works: it provides a signal the body does not produce in the same way on its own, and when the signal is removed, appetite and metabolism tend to return towards their previous state. Researchers are actively studying how best to maintain results over the long term.

Is Ozempic a Peptide or a Steroid?

This is one of the most common questions people search for, and the answer is clear: semaglutide is a peptide, not a steroid. Steroids are built on a skeleton of four fused carbon rings made from cholesterol, and they act mainly on receptors inside cells that switch genes on and off. Semaglutide is a chain of amino acids that acts on the GLP-1 receptor on the outside of cells. The two families are chemically unrelated. Our article peptides vs steroids explains the difference in detail.

Is Ozempic a Hormone?

Semaglutide is a modified version of a hormone, GLP-1, and acts on the same receptor, so it is accurate to call it a peptide hormone analogue. It is not a hormone replacement in the sense of topping up a hormone the body lacks; rather, it provides a much longer-lasting version of a signal the body normally makes in brief bursts after meals.

The Next Generation: Beyond GLP-1 Alone

Tirzepatide

The success of semaglutide sparked a wave of new peptides. Tirzepatide, a 39-amino-acid peptide, acts on both the GLP-1 receptor and the receptor for GIP, the other main incretin hormone. In the SURMOUNT-1 trial, published in 2022, it produced mean weight reductions of up to about 21% over 72 weeks (PMID: 35658024).

Retatrutide

Retatrutide goes a step further, acting on three receptors: GLP-1, GIP and glucagon. In a 2023 phase 2 trial in the New England Journal of Medicine, it produced mean weight reductions of up to 24.2% at 48 weeks in the highest-dose group (PMID: 37366315). Our article retatrutide vs tirzepatide compares them.

A family of multi-receptor peptides

These medicines show how peptide design has moved from copying a single hormone to combining several hormone signals in one molecule, a remarkable achievement of modern chemistry. Research compounds in this area are grouped in our metabolic research peptides category.

How Ozempic Changed Peptide Science

Public awareness

Before the GLP-1 boom, peptides were mostly discussed by scientists and specialists. Semaglutide made “peptide” a word people recognised, and interest in the whole field, from research compounds to skincare, rose with it.

Investment and research

The commercial success of GLP-1 medicines drove enormous investment in peptide research and manufacturing, accelerating work on oral peptides, longer-acting peptides and multi-receptor designs. A 2021 review in Nature Reviews Drug Discovery by Muttenthaler and colleagues described the broader trends in peptide therapeutics that this success has amplified (PMID: 33536635).

New questions

The GLP-1 medicines have also opened scientific questions far beyond weight and blood sugar, as researchers study their effects on the heart, kidneys, liver and brain. Metabolism research as a whole has been re-energised, including interest in other metabolic signalling molecules such as the mitochondrial peptide MOTS-c and the NNMT inhibitor 5-Amino-1MQ.

A darker side: counterfeits

Enormous demand has also brought fake products. Regulators in the UK and worldwide have warned about counterfeit semaglutide and unlicensed products sold online. Studies of falsified peptide products have found very low purity and contamination with toxic metals (PMID: 30029448). Licensed semaglutide is a prescription-only medicine in the UK.

Other Famous Peptide Medicines

Semaglutide is the most famous peptide medicine of the moment, but it joins a long line.

Insulin

Insulin, first used in 1922, transformed type 1 diabetes from a fatal disease into a manageable one and remains one of the most important medicines in the world.

Oxytocin

The first peptide hormone to be synthesised, in 1953, and used in childbirth ever since.

Octreotide

A stabilised version of the hormone somatostatin, used since the 1980s for hormone-secreting tumours and other conditions.

Teriparatide

A fragment of parathyroid hormone used to build bone in osteoporosis, one of the few medicines that actively increases bone formation.

The pattern

Each of these, like semaglutide, takes a natural peptide signal and either copies it or makes it more durable. That pattern, borrowing from biology and improving on it with chemistry, is the heart of peptide medicine.

Common Myths About Ozempic and Peptides

“It is just a diet drug”

Semaglutide was developed for type 2 diabetes and acts on several systems, including insulin release, stomach emptying and appetite centres in the brain. Its weight effects are one part of a broader metabolic profile.

“All peptides work like Ozempic”

Peptides are an enormous and diverse family. Semaglutide acts on one specific receptor. A tissue repair peptide, a copper peptide or a growth hormone releasing peptide acts on completely different targets and has nothing to do with GLP-1.

“It is a steroid”

It is not. It is a peptide, chemically unrelated to steroids.

“Compounded or online versions are the same”

Licensed semaglutide is made under strict manufacturing standards. Products from unregulated sources may not contain what they claim, and regulators have warned repeatedly about counterfeits.

What GLP-1 Research Means for the Wider Peptide Field

The GLP-1 story offers several lessons that apply across peptide science. It shows that natural peptide signals can be turned into powerful tools when their weaknesses, rapid breakdown and short action, are solved with careful chemistry. It shows that the most transformative results often come from understanding a natural system deeply before trying to change it. And it shows that even for the most successful peptides, large, careful trials are what reveal both the true size of the benefits and the real side effects. For researchers working with peptides in the laboratory, those lessons are a useful guide: precise questions, well-understood mechanisms, verified materials and honest measurement of effects in every direction.

How Semaglutide Differs From Research Peptides

Semaglutide is a licensed medicine: it was made under Good Manufacturing Practice, tested in large clinical trials and authorised by regulators for specific uses, and it is prescribed and monitored by clinicians. Research peptides are supplied for laboratory research, have not been through that process and are not medicines. Crown Peptides does not sell semaglutide. Our article what the research-use label means explains the distinction.

The Oral Semaglutide Puzzle

One of the most impressive feats in the semaglutide story is Rybelsus, the tablet. Peptides are normally destroyed in the digestive system: stomach acid and enzymes break them down into amino acids, and the gut lining is built to keep large molecules out. Rybelsus overcomes this by pairing semaglutide with SNAC, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate. SNAC works locally in the stomach, briefly raising the pH around the tablet to protect semaglutide from digestive enzymes and helping it cross the stomach lining. Even so, only a small fraction of each dose is absorbed, which is why tablet strengths are much higher than injected ones. It remains one of very few oral peptide medicines, and a sign of how much effort goes into getting peptides into the body in usable form.

Why Peptide Manufacturing Matters Here

Semaglutide’s 31 amino acids, unusual building block and attached fatty acid make it a demanding molecule to manufacture. Every step must be controlled to avoid deletion sequences, incorrect amino acids or incomplete attachment of the fatty acid chain, any of which would change how it behaves. That complexity is one reason counterfeit and unlicensed products are a concern: making a peptide like this correctly requires sophisticated chemistry, purification and testing, and there is no way to tell a good product from a poor one by eye. The same principle applies to every research peptide, which is why independent HPLC and mass spectrometry verification matters so much.

The Technical Breakdown: How GLP-1 Receptor Signalling Works

The receptor

The GLP-1 receptor is a class B G protein-coupled receptor found on insulin-producing beta cells in the pancreas, in the stomach and gut, in the heart and blood vessels, and in several brain regions involved in appetite. When semaglutide binds, the receptor activates a Gs protein, raising cyclic AMP inside the cell.

In the pancreas

In beta cells, rising cyclic AMP amplifies insulin release, but only when blood sugar is elevated. That glucose dependence is why GLP-1-based medicines carry a lower risk of dangerously low blood sugar than insulin itself when used alone.

In the brain

GLP-1 receptors in the hypothalamus and brainstem influence appetite and fullness. Albumin-bound semaglutide is thought to reach certain brain regions near the blood-brain barrier’s more permeable areas, which may explain its strong effect on appetite.

Albumin binding

Albumin circulates for around three weeks. By binding to it reversibly, semaglutide is protected from breakdown and from filtering by the kidneys, and is released gradually, producing its roughly week-long half-life.

Related Reading

To understand the science behind peptides more broadly, read what are peptides, peptide half-life explained and are peptides safe. For metabolic research compounds, see NAD+, AOD-9604, L-Carnitine and the Metabolic Research Bundle.

Ozempic Questions, Answered

Is Ozempic a peptide?

Yes. Its active ingredient, semaglutide, is a modified 31-amino-acid peptide closely based on the natural hormone GLP-1.

Is Ozempic a peptide or a steroid?

A peptide. It is chemically unrelated to steroids and works through a different kind of receptor.

Is Ozempic a hormone?

It is a long-acting analogue of the gut hormone GLP-1, acting on the same receptor as the natural hormone.

Is Ozempic a peptide drug?

Yes. It is one of more than 80 peptide medicines that have reached the market since insulin.

Why does semaglutide last a week?

Because it is modified to resist the enzyme DPP-4 and carries a fatty acid chain that binds albumin in the blood, protecting it and releasing it slowly.

How does semaglutide cause weight loss?

Mainly by reducing appetite through GLP-1 receptors in the brain’s appetite centres, and by slowing stomach emptying, which prolongs fullness after meals.

Who discovered GLP-1?

GLP-1 was identified in the 1980s by researchers including Joel Habener, Svetlana Mojsov and Daniel Drucker in Boston and Jens Juul Holst in Copenhagen, who found it while studying the gene for glucagon.

Why was a lizard involved in the GLP-1 story?

Because the venom of the Gila monster contains exendin-4, a peptide that acts on the GLP-1 receptor but resists breakdown. It became exenatide, the first GLP-1 medicine, approved in 2005.

Is there a tablet version of Ozempic?

The same molecule is available as a tablet under the name Rybelsus, using an absorption enhancer called SNAC to help it survive the stomach and cross its lining.

What is the difference between semaglutide and tirzepatide?

Semaglutide acts on the GLP-1 receptor alone. Tirzepatide is a separate 39-amino-acid peptide that acts on both the GLP-1 and GIP receptors.

Does Crown Peptides sell semaglutide?

No. Semaglutide is a prescription-only medicine in the UK. Crown Peptides supplies research compounds for laboratory work.

What is the difference between Ozempic and Wegovy?

Both contain semaglutide. Ozempic is licensed for type 2 diabetes; Wegovy is licensed for weight management, at a higher strength.

The Peptide That Changed the Conversation

Semaglutide is a peptide in every sense: a chain of amino acids, closely modelled on a natural gut hormone, refined through decades of chemistry that began with the discovery of GLP-1 and a lizard’s venom. Its success has shown the world what peptide science can do, and it has pulled an entire field, from metabolic research to skincare, into the spotlight. Whatever comes next, it is likely to be built on the same principles: a natural sequence for precision, and clever modifications for durability.

For laboratory research into metabolic signalling, explore the Crown Peptides metabolic research range, every batch HPLC and mass spectrometry verified and dispatched from the UK.